Good morning … Columbus, Ohio: Join Axios’ Mike Allen tomorrow morning at The King Arts Complex for a breakfast conversation on the future of work.
To hear how jobs are changing, he’ll be interviewing: Jamie Dimon, JPMorgan Chase & Co. CEO; Josh Silverman, Etsy CEO; Francis Davidson, Sonder CEO; and Columbus’ own Jeni Britton Bauer, of Jeni’s Splendid Ice Creams. RSVP here.
Maximilian Muench makes his living from travel photos. The same model is increasingly applying to prescription drugs. Photo: Paul Zinken/Picture alliance via Getty Images
Social-media influencers aren’t just promoting clothes and fancy hotels any more — they’re now helping to sell prescription drugs.
Most of these influencers are patients, according to STAT. They sign up with talent agencies, and then pharmaceutical companies come to those agencies looking for a patient willing to promote a particular drug.
There are no restrictions on who can promote a drug, and if a campaign discusses a condition rather than a specific product, drug companies don’t have to disclose their involvement.
The Centers for Medicare and Medicaid Services announced yesterday that states can soon begin applying for waivers to expand their treatment capacity for serious mental health issues, Axios' Caitlin Owens reports.
Why it matters: Experts say the IMD exclusion is a big obstacle to treatment for low-income people.
A new policy buried within Medicare’s large 2019 outpatient rule changes how the federal program will pay for Exparel, a non-opioid pain reliever used after surgeries, my colleague Bob Herman reports.
Starting next year, Medicare will add a 6% markup for Exparel if a patient gets the drug in a surgery center. Currently, Medicare pays for Exparel through a lower packaged rate.
Between the lines: Medicare's decision, which did not follow the advice of the Medicare Payment Advisory Commission, will boost revenue for Pacira Pharmaceuticals, the maker of Exparel.
The big picture: Medicare officials did not approve higher pay for Exparel in hospital outpatient departments, but it’s still a big win for the company — especially in light of the fact that several experts say the drug is not worth its high price.
Dsuvia, the potent new opioid the FDA approved last week, is a solution in search of a problem, experts told Business Insider.
How it works: Dsuvia is an oral formulation of an existing product that’s delivered via an injection. Its proponents say it will be useful in situations where an IV isn’t feasible — for example, on the battlefield, or for patients whose veins are hard to find.
The other side: "There are plenty of low-cost solutions out there if this is a systems problem. But this would be a very complicated and round-about way of solving that issue. It's like engineering overkill,” Ernest Rasyidi, a psychiatrist at St. Joseph Hospital in Orange, California, told Business Insider.